GB201709959D0 - Small molecule modulators of human STING - Google Patents

Small molecule modulators of human STING

Info

Publication number
GB201709959D0
GB201709959D0 GBGB1709959.9A GB201709959A GB201709959D0 GB 201709959 D0 GB201709959 D0 GB 201709959D0 GB 201709959 A GB201709959 A GB 201709959A GB 201709959 D0 GB201709959 D0 GB 201709959D0
Authority
GB
United Kingdom
Prior art keywords
small molecule
molecule modulators
human sting
sting
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB1709959.9A
Other versions
GB2563642A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curadev Pharma Ltd
Original Assignee
Curadev Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curadev Pharma Ltd filed Critical Curadev Pharma Ltd
Priority to GB1709959.9A priority Critical patent/GB2563642A/en
Publication of GB201709959D0 publication Critical patent/GB201709959D0/en
Priority to JP2020520838A priority patent/JP2020524717A/en
Priority to BR112019027127-9A priority patent/BR112019027127A2/en
Priority to UAA202000289A priority patent/UA125730C2/en
Priority to US16/625,032 priority patent/US20200138827A1/en
Priority to PCT/GB2018/051730 priority patent/WO2018234808A1/en
Priority to US16/625,047 priority patent/US11571423B2/en
Priority to PE2019002587A priority patent/PE20200696A1/en
Priority to JP2020520840A priority patent/JP7296954B2/en
Priority to EP18737372.5A priority patent/EP3642198B1/en
Priority to PCT/GB2018/051727 priority patent/WO2018234805A1/en
Priority to EP18737370.9A priority patent/EP3642184A1/en
Priority to TW107121352A priority patent/TWI799426B/en
Priority to SG11201912397RA priority patent/SG11201912397RA/en
Priority to CN201880054141.8A priority patent/CN111132972B/en
Priority to MX2019015468A priority patent/MX2019015468A/en
Priority to AU2018288018A priority patent/AU2018288018C1/en
Priority to KR1020207001712A priority patent/KR102628892B1/en
Priority to CA3067257A priority patent/CA3067257A1/en
Publication of GB2563642A publication Critical patent/GB2563642A/en
Priority to ARP190101730A priority patent/AR114975A1/en
Priority to PH12019502870A priority patent/PH12019502870A1/en
Priority to IL271522A priority patent/IL271522B2/en
Priority to ZA2019/08496A priority patent/ZA201908496B/en
Priority to CL2019003793A priority patent/CL2019003793A1/en
Priority to CONC2020/0000562A priority patent/CO2020000562A2/en
Priority to ECSENADI20204580A priority patent/ECSP20004580A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB1709959.9A 2017-06-22 2017-06-22 Small molecule modulators of human STING Withdrawn GB2563642A (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
GB1709959.9A GB2563642A (en) 2017-06-22 2017-06-22 Small molecule modulators of human STING
CA3067257A CA3067257A1 (en) 2017-06-22 2018-06-21 Small molecule modulators of human sting
TW107121352A TWI799426B (en) 2017-06-22 2018-06-21 Small molecule modulators of human sting
CN201880054141.8A CN111132972B (en) 2017-06-22 2018-06-21 Small molecule modulators of human STING
UAA202000289A UA125730C2 (en) 2017-06-22 2018-06-21 Small molecule modulators of human sting
US16/625,032 US20200138827A1 (en) 2017-06-22 2018-06-21 Small molecule modulators of human sting
PCT/GB2018/051730 WO2018234808A1 (en) 2017-06-22 2018-06-21 Small molecule modulators of human sting
US16/625,047 US11571423B2 (en) 2017-06-22 2018-06-21 Small molecule modulators of human sting
PE2019002587A PE20200696A1 (en) 2017-06-22 2018-06-21 HUMAN STING SMALL MOLECULES MODULATORS
JP2020520840A JP7296954B2 (en) 2017-06-22 2018-06-21 Small Molecule Regulators of Human STING
EP18737372.5A EP3642198B1 (en) 2017-06-22 2018-06-21 Small molecule modulators of human sting
PCT/GB2018/051727 WO2018234805A1 (en) 2017-06-22 2018-06-21 Small molecule modulators of human sting
EP18737370.9A EP3642184A1 (en) 2017-06-22 2018-06-21 Small molecule modulators of human sting
JP2020520838A JP2020524717A (en) 2017-06-22 2018-06-21 Small molecule regulator of human STING
SG11201912397RA SG11201912397RA (en) 2017-06-22 2018-06-21 Small molecule modulators of human sting
BR112019027127-9A BR112019027127A2 (en) 2017-06-22 2018-06-21 small molecule human sting modulators
MX2019015468A MX2019015468A (en) 2017-06-22 2018-06-21 Small molecule modulators of human sting.
AU2018288018A AU2018288018C1 (en) 2017-06-22 2018-06-21 Small molecule modulators of human STING
KR1020207001712A KR102628892B1 (en) 2017-06-22 2018-06-21 Small molecule modulators of human STING
ARP190101730A AR114975A1 (en) 2017-06-22 2019-06-21 HUMAN STING SMALL MOLECULE MODULATORS, CONJUGATES AND THERAPEUTIC APPLICATIONS
PH12019502870A PH12019502870A1 (en) 2017-06-22 2019-12-18 Small molecule modulators of human sting
IL271522A IL271522B2 (en) 2017-06-22 2019-12-18 Small molecule modulators of human sting
ZA2019/08496A ZA201908496B (en) 2017-06-22 2019-12-19 Small molecule modulators of human sting
CL2019003793A CL2019003793A1 (en) 2017-06-22 2019-12-20 Small molecule modulators of human sting.
CONC2020/0000562A CO2020000562A2 (en) 2017-06-22 2020-01-20 Human sting small molecule modulators
ECSENADI20204580A ECSP20004580A (en) 2017-06-22 2020-01-21 HUMAN STING SMALL MOLECULE MODULATORS

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1709959.9A GB2563642A (en) 2017-06-22 2017-06-22 Small molecule modulators of human STING

Publications (2)

Publication Number Publication Date
GB201709959D0 true GB201709959D0 (en) 2017-08-09
GB2563642A GB2563642A (en) 2018-12-26

Family

ID=59523644

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1709959.9A Withdrawn GB2563642A (en) 2017-06-22 2017-06-22 Small molecule modulators of human STING

Country Status (1)

Country Link
GB (1) GB2563642A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114981256A (en) * 2019-08-21 2022-08-30 斯克里普斯研究学院 Single-ring agonists of the interferon gene stimulator STING

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2574913A (en) * 2017-06-22 2019-12-25 Curadev Pharma Ltd Small molecule modulators of human STING, conjugates and therapeutic applications
SG11201912397RA (en) 2017-06-22 2020-01-30 Curadev Pharma Ltd Small molecule modulators of human sting
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
CN113950473A (en) * 2019-06-12 2022-01-18 雷沃医疗有限公司 Next generation modulators of interferon gene Stimulators (STING)
AU2020291796B2 (en) * 2019-06-12 2024-01-18 Ryvu Therapeutics S.A. Next-generation modulators of stimulator of interferon genes (STING)
GB201910305D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
EP4017593A1 (en) * 2019-08-21 2022-06-29 The Scripps Research Institute Bicyclic agonists of stimulator of interferon genes sting
CA3159943A1 (en) * 2019-12-11 2021-06-17 Magdalena Izabela ZAWADZKA Functionalized heterocyclic compounds as modulators of stimulator of interferon genes (sting)
AU2020400010B2 (en) * 2019-12-11 2024-01-25 Ryvu Therapeutics S.A. Heterocyclic compounds as modulators of Stimulator of Interferon Genes (STING)
AU2021338438A1 (en) * 2020-09-02 2023-03-23 The Scripps Research Institute Agonists of stimulator of interferon genes sting

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7960376B2 (en) * 2007-09-14 2011-06-14 Cara Therapeutics, Inc. Benzo-fused heterocycles
WO2009086303A2 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2009120660A2 (en) * 2008-03-28 2009-10-01 Cara Therapeutics, Inc. Substituted pyridoxazines
WO2011073276A1 (en) * 2009-12-16 2011-06-23 Evotec Ag Benzoxazine aryl sulfonamide derivatives as kv1.3 modulators
CA2977588C (en) * 2015-03-02 2023-10-03 Apeiron Biologics Ag Bicyclic tetrahydrothiazepine derivatives useful for the treatment of neoplastic and/or infectious diseases
US20170146519A1 (en) * 2015-11-20 2017-05-25 Oregon Health & Science University Sting agonists and methods of selecting sting agonists

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114981256A (en) * 2019-08-21 2022-08-30 斯克里普斯研究学院 Single-ring agonists of the interferon gene stimulator STING

Also Published As

Publication number Publication date
GB2563642A (en) 2018-12-26

Similar Documents

Publication Publication Date Title
ZA201908496B (en) Small molecule modulators of human sting
GB201709959D0 (en) Small molecule modulators of human STING
IL283582A (en) Modulators of ror-gamma
HK1256599A1 (en) Modulators of ror-gamma
IL248604A0 (en) Cyclic di-nucleotides as modulators of sting
IL274570A (en) Sting modulator compounds, and methods of making and using
HK1251486A1 (en) Modulators of sestrin-gator2 interaction and uses thereof
IL281492A (en) Modulators of pnpla3 expression
IL304618A (en) Modulators of pcsk9 expression
IL283967A (en) Modulators of hsd17b13 expression
HK1249384A1 (en) Cosmetic instrument
HK1255425A1 (en) Application member and medical instrument
GB201709958D0 (en) Heterocyclic small molecule modulators of human STING
PL3449931T3 (en) Use of cerebrolysin
IL274231A (en) Modulators of enac expression
GB201705177D0 (en) Device to aid movement of substance from the eye
IL271359A (en) Modulators of alpha-synuclein
GB201810172D0 (en) Azaheteocyclic small molecule modulators of human sting
HUE051041T2 (en) Use of isothiocyanate derivatives as modulators of peripheral and neuropathic pain
GB201820991D0 (en) Small molecule modulators of human STING, conjugates and therapeutic applications
MA50034A (en) COMPOSITION OF CONTROLLED OVARIAN STIMULATION
ES2981316T3 (en) Treatment of fibrosis with inositol
UA36244S (en) MASSAGER
UA36245S (en) MASSAGER
UA36356S (en) MASSAGER

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)